Cannasat Therapeutics

Cannasat Therapeutics (now Cynapsus Therapeutics Inc.) is a publicly traded (CTH: TSXV) clinical-stage pharmaceutical company developing products to treat neurological conditions such as neuropathic pain and schizophrenia. Cannasat is currently investigating two drug candidates, CAT 310 and CAT 320.